Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries

Co-Founder & CEO Daniela Marino describes why CUTISS believes denovoSKIN is superior to autografting. She describes how they make it, walks us through the company's on-site GMP facility, and she discusses the clinical experience to date. The therapy is already in a phase 3 study in Europe.